SRPT

Sarepta Therapeutics, Inc. Press Releases

$31.92
*  
0.16
0.5%
Get SRPT Alerts
*Delayed - data as of Jul. 31, 2015  -  Find a broker to begin trading SRPT now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By



Sarepta Therapeutics to Announce Second Quarter 2015 Financial Results and Recent Corporate Developments on August 6, 2015
7/30/2015 8:30:00 AM - Business Wire
▲3.30 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platform
7/22/2015 5:01:00 PM - Business Wire
▼-5.17 % Price Change since this news event. The Volume Ratio is 0.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company
7/1/2015 8:30:00 AM - Business Wire
▲4.90 % Price Change since this news event. The Volume Ratio is 0.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/30/2015 5:16:00 PM - Business Wire
▲5.49 % Price Change since this news event. The Volume Ratio is 0.66.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
6/29/2015 7:00:00 AM - Business Wire
▲4.66 % Price Change since this news event. The Volume Ratio is 2.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5/29/2015 5:00:00 PM - Business Wire
▲24.59 % Price Change since this news event. The Volume Ratio is 0.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDA
5/19/2015 4:00:00 PM - Business Wire
▲94.75 % Price Change since this news event. The Volume Ratio is 21.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/12/2015 4:30:00 PM - Business Wire
▲109.86 % Price Change since this news event. The Volume Ratio is 0.52.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day